We have selected the very best, internationally distinguished speakers to cover this field. Topics include PIDs with a well-known increased risk of malignancy.
Issues regarding pathogenesis, diagnosis, treatment and screening will be approached from different viewpoints.
We have included the ESID “classics” such as “Meet-the-Expert” sessions to update you with the newest findings in PID. The educational program will as usual be organised on the first day and throughout the Meeting education will be a priority.
Have a look at the programme timetable to get an idea of the exciting sessions you can expect in Brussels.
*The programme is subject to change. Last updated: August 28, 2019.
** For better view of the programme at a glance use the zoom option in the .pdf format.
MUTATIONS, AUTOIMMUNITY AND LYMPHOID CANCER. Christopher Goodnow (Australia)
MALIGNANCY IN PID: BASIS AND INCIDENCE
- INCREASED RISK OF MALIGNANCY IN PID: SETTING THE SCENE. Markus Seidel (Austria)
- INCREASED RISK OF LYMPHOMA IN CTLA4 AND LRBA DEFICIENCY. Bodo Grimbacher (Germany)
- INCIDENCE OF MALIGNANCY IN CVID. Isabella Quinti (Italy)
- LYMPHOMA AND LYMPHOPROLIFERATION UNDER THE MICROSCOPE: THE THIN LINE. Christopher Bacon (UK)
GENES IN CANCER AND PID
- IKAROS IN PID: A DIVERSE FIELD. Sergio D. Rosenzweig (USA)
- IKAROS IN LEUKEMIA. Geertruy te Kronnie (Italy)
- PI3K IN CANCER. David Fruman (USA)
- JAK-STAT PATHWAY: TRIUMPHS AND PIFTALLS OF BIOLOGICALS. Steven Holland (USA)
ATM AND BEYOND
- MOLECULAR MECHANISMS: ROLE OF ATM IN THE IMMUNE SYSTEM. Malcolm Taylor (UK)
- CANCER IN AT: DATA FROM THE FRENCH NATIONAL REGISTRY. Felipe Suarez (France)
- MULTIDISCIPLINARY TREATMENT IN AT. Jan Loeffen (The Netherlands)
- OFF-TARGET EFFECTS OF NEW CANCER TREATMENT STRATEGIES
EBV, PID AND MALIGNANCY
- IMMUNITY AGAINST EBV: GENERAL OVERVIEW. Stuart Tangye (Australia)
- INBORN ERRORS OF IMMUNITY TO EBV. Sylvain Latour (France)
- EBV AND ONCOGENESIS: GENERAL OVERVIEW. (INCL NASOPHARYNGEAL CARCINOMA, BURKITT LYMPHOMA)
- CARMIL2 DEFICIENCY AND EBV INDUCED MALIGNANCY. Fabian Hauck (Germany)
REPAIR AND SURVEILLANCE
- DNA REPAIR MECHANISMS AND HOW TO EXPLOIT THE SYSTEM AGAINST CANCER. Haico van Attikum (The Netherlands)
- CGAS: A CELL-INTRINSIC IMMUNE SURVEILLANCE MECHANISM? Karen Mackenzie (UK)
- ONE TUMOR ONE PID? Alain Fischer (France)
CANCER AND IMMUNITY: SURVIVAL OF THE FITTEST
- CAR T CELLS: GIANTS AGAINST CANCER. Waseem Qasim (UK)
- TARGETED TREATMENT FOR CANCER: EXPLOITING THE IMMUNE SYSTEM TO TREAT CANCER. Kris Thielemans (Belgium)
- INBORN ERRORS OF IMMUNITY AGAINST ONCOGENIC VIRUSES. Jean-Laurent Casanova (USA)
THE IMMUNOLOGY OF THE TUMOR-MICROENVIRONMENT: IMPACT ON CANCER PROGRESSION, INVASION, RECURRENCE, AND SURVIVAL OF PATIENT. Jerome Galon (France)
- DNA Repair Disorders
- Lymphoproliferation and Lymphoma: The Thin Line. Flashes
- DNA Repair and Breakage Disorders
- LCH And Cutaneous T Cell Lymphoma
- MDS and BMF Syndromes
- Other Viruses and Mechanisms Involved in Malignancy and PID
MTE – MEET THE EXPERT SESSIONS
- Pattern Recognition in PID
- Newborn Screening -Managing the Results
- How to Investigate and Treat the Adult with Antibody Deficiency?
- Malignancy in WAS
- Secondary Malignancies After Cancer Treatment
- Investigating and Managing Neutropenia and Bone Marrow Failure
- Who and When to Transplant? Secondary Cancer Post HSCT for PID
WORKING PARTY SESSIONS
- WP – Clinical
- WP – Genetics
- WP – Registry
- WP – Junior
- WP – PID care in development
- WP – Inborn Errors
The first day of the meeting will be dedicated to our highly acclaimed educational programme with further sessions throughout the meeting with world-class teachers bringing high quality educational lectures and interactive sessions which will be of great benefit to students, trainees and established clinicians and scientists with practical and relevant up-date current insights into pathogenesis, recognition and management of immune disorders.
The International Nursing Group for Immunodeficiencies (INGID) was formed in 1994 by nurses who were working with children and adults diagnosed with primary immunodeficiency disorders.
The aims of INGID are to improve and extend the quality of nursing care of patients with primary immune deficiencies, and to increase the awareness and understanding of primary immunodeficiencies amongst nurses.
INGID will have sessions run September 18 – September 20 in silver hall. These sessions are not included into the main CME/CPD event.